An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1

Journal of Medical Virology

Volumn 84, Issue 3, 2012, Pages 394-401

  Lee, Chun Kiat ^a   Lee, Hong Kai ^a,b   Loh, Tze Ping ^a   Sethi, Sunil Kumar ^a,b   Koay, Evelyn Siew Chuan ^a,b   Tang, Julian Wei Tze ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

C terminal domain; Gag pol region; Protease; Reverse transcriptase; Sequencing

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CODON; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHEAST ASIA; STRUCTURAL GENE;

ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862915276     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23202     Document Type: Article

References (31)

1. Cane PA, Green H, Fearnhill E, Dunn D, UK Collaborative Group on HIV Drug Resistance. 2007. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 21: 447-455.
2. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A. 2000. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 275: 107-115.
3. Chen JHK, Wong KH, Chan K, Lam HY, Lee SS, Li P, Lee MP, Tsang DN, Zheng BJ, Yuen KY, Yam WC. 2007. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 39: 125-131.
4. Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT, UK Collaborative Group on HIV Drug Resistance. 2010. HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther 15: 985-991.
5. Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. 2010. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr 54: 160-166.
6. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. 2010. The "connection" between HIV drug resistance and RNase H. Viruses 2: 1476-1503.
7. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. 2010. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 13: 1-9.
8. EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. AIDS 15: 309-320.
9. Fokam J, Salpini R, Santoro MM, Cento V, D'Arrigo R, Gori C, Perno CF, Colizzi V, Nanfack A, Gwom LC, Cappelli G, Takou D. 2011. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol 156: 1235-1243.
10. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D, UK Collaborative Group on HIV Drug Resistance. 2009. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 48: 1296-1305.
11. Goulden MG, Cammack N, Hopewell PL, Penn CR, Cameron JM. 1996. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 10: 101-102.
12. Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ. 2010. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: Assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother 54: 1973-1980.
13. Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD. 2002. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 76: 6836-6840.
14. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD, International AIDS Society-USA. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 16: 266-285.
15. Huang DD, Eshleman SH, Brambilla DJ, Palumbo PE, Bremer JW. 2003. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol 41: 3265-3272.
16. Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D, UK Collaborative Group on HIV Drug Resistance. 2009. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol 83: 2645-2654.
17. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′, 3′-dideoxy-3′-thiacytidine. J Virol 72: 5093-5098.
18. McCutchan FE. 2006. Global epidemiology of HIV. J Med Virol 78: S7-S12.
19. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, Coffin JM, Pathak VK. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 104: 317-322.
20. Peduzzi C, Pierotti P, Venturi G, Romano L, Mazzotta F, Zazzi M. 2002. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors. J Clin Virol 25: 57-62.
21. Pelemans H, Esnouf RM, Jonckheere H, De Clercq E, Balzarini J. 1998. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J Biol Chem 273: 34234-34239.
22. Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, Rojanawiwat A, Kannagi M, Ariyoshi K, Sugiura W. 2010. Drug-resistant mutation patterns in CRF01-AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. Antiviral Res 87: 22-29.
23. Santos AF, Lengruber RB, Soares EA, Jere A, Sprinz E, Martinez AM, Silveira J, Sion FS, Pathak VK, Soares MA. 2008. Conservation patterns of HIV-1 RT connection and RNase H domains: Identification of new mutations in NRTI-treated patients. PLoS ONE 12: 1-7.
24. Saravanan S, Vidya M, Balakrishanan P, Kumarasamy N, Solomon SS, Solomon S, Kantor R, Katzenstein D, Ramratnam B, Mayer KH. 2009. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods 159: 211-216.
25. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, Mandaliya K, Plum J, Verhofstede C. 2006. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods 133: 137-145.
26. Tanuma J, Hachiya A, Ishigaki K, Gatanaga H, Lien TT, Hien ND, Kinh NV, Kaku M, Oka S. 2010. Impact of CRF01-AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect 12: 1170-1177.
27. Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G, GenPheRex PhenGen Study Groups of the MASTER Cohort. 2004. HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: Genotypic-phenotypic correlations. J Acquir Defic Syndr 36: 1104-1107.
28. UNAIDS. 2008. UNAIDS 2008 report on the global AIDS epidemic.
29. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TFR, Stevens W. 2010. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 163: 505-508.
30. Xu S, Zhong P, Li J, Song A, Li H, Nie J, Li X, Wang Y. 2011. Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug resistance mutations in China. Mol Diagn Ther 15: 41-52.
31. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 4: 1887-1900.